RCEL Should I Buy
This article analyzes whether AVITA Medical Inc (RCEL) is a strong buy for investors, concluding with a "Hold" recommendation. Despite positive catalysts like increased hedge fund buying and an Outperform rating from Northland analysts, technical indicators are bearish, and the company's financial performance shows declining revenue and EPS. The analysis suggests waiting for more favorable conditions before considering a purchase.
AVITA Medical (RCEL) files $200M S-3 shelf to sell stock, warrants
AVITA Medical, Inc. (RCEL) has filed an S-3 shelf registration statement to offer up to $200 million in common stock, preferred stock, warrants, and units. The company intends to use the net proceeds for general corporate purposes, including capital expenditures and working capital. Specific terms of each offering, such as pricing and distribution methods, will be detailed in future prospectus supplements.
AVITA Medical (RCEL) Price Target Decreased by 14.77% to 7.65
AVITA Medical (RCEL) has seen its price target reduced by 14.77% to $7.65. This adjustment suggests a change in analyst outlook regarding the company's future stock performance.
AVH Stock Price and Chart — ASX:AVH
This article provides an overview of AVITA Medical (ASX:AVH) stock, including its current price performance, financial highlights, key statistics, and company profile. It details the company's product, RECELL system, used for autologous skin restoration. The page also features a community-driven "Ideas" section with technical analysis and trading strategies related to AVH and RCEL stocks from various contributors.
If You Invested $1,000 in Avita Medical Inc (RCEL)
This article analyzes the historical performance of a $1,000 investment in Avita Medical Inc (RCEL) over 1, 5, and 10 years, showing significant losses and underperformance compared to the S&P 500. It also provides a detailed overview of Avita Medical Inc, including its core products like the RECELL System, regulatory footprint, clinical evidence, and financial structure. The company is primarily focused on therapeutic acute wound care using autologous skin cell suspension and dermal matrices.
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from Analysts
Avita Medical Inc. (NASDAQ:RCEL) has received a consensus "Hold" rating from six analysts, with an average 12-month price target of $6.63. The stock opened at $3.95, trading below its 50-day and 200-day moving averages, and institutional investors have recently shown increased interest. The company specializes in regenerative medicine for acute and chronic wounds.
AVITA Medical (RCEL) CFO adds 1,800 shares in open-market purchase
AVITA Medical (RCEL) CFO David D. O'Toole purchased 1,800 shares of common stock in an open-market transaction at $4.78 per share on March 11, 2026. This acquisition increases his direct holdings to 141,927 shares, which include unvested restricted stock units. The purchase is categorized as a neutral filing impact and sentiment, signaling potential personal confidence in the company by the executive.
Insider Buying: David O'Toole Acquires Shares of AVITA Medical I
David O'Toole, CFO of AVITA Medical Inc (RCEL), recently purchased 1,800 shares, increasing his total holdings to 141,927 shares. This transaction is part of a trend of six insider buys with no sells over the past year, indicating positive insider sentiment. Although the stock's current trading price of $4.78 and market cap of $147.033 million suggest it might be a "Possible Value Trap" based on its GF Value of $12.58, the insider buying activity could interest investors.
Northland Securities Predicts Avita Medical Q1 Earnings
Northland Securities analysts predict that Avita Medical Inc. (NASDAQ:RCEL) will report a Q1 2026 loss of $0.35 per share, with a full-year consensus estimate of a $0.95 per share loss. The firm maintains an "Outperform" rating and a $10.00 target price on the stock. These forecasts for the regenerative medicine company are crucial for investor sentiment and will be closely watched.
AVITA Medical (RCEL) director Woody Fralin files initial Form 3
AVITA Medical, Inc. director Woody Joseph Fralin has filed an initial Statement of Beneficial Ownership (Form 3) with the SEC. The filing indicates his role as a director of the company and reports no beneficial ownership of AVITA Medical, Inc. securities (no purchases, sales, acquisitions, or dispositions). This form is typically filed when an individual first becomes an insider (director, officer, or 10% owner) of a company.
Avita Medical (NASDAQ:RCEL) Now Covered by Analysts at Northland Securities
Northland Securities has initiated coverage on Avita Medical (NASDAQ:RCEL) with an "outperform" rating and a $10.00 price target, suggesting a potential upside of over 100%. The company currently holds an average "Hold" rating from analysts with a consensus price target of $6.63. Avita Medical, a regenerative medicine company, opened at $4.96 with a market capitalization of $151.9 million.
RCEL - AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
AVITA Medical reported its financial results for the fourth quarter and full year ended December 31, 2025. The company achieved total revenues of $17.6 million for Q4 2025 and $71.6 million for the full year 2025, an 11% increase from 2024, despite reimbursement challenges. AVITA Medical also announced a new credit facility securing up to $60 million in capital and provided a revenue guidance of $80-$85 million for full year 2026.
RCEL SEC Filings - Avita Medical Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Avita Medical (RCEL) SEC filings, including 10-K, 10-Q, and 8-K reports. It details the company's financial condition, governance, and material business developments related to its therapeutic acute wound care products. The platform also offers AI-powered summaries and real-time updates for these regulatory documents.
RCEL Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Avita Medical Inc (RCEL) for fiscal year 2025, including detailed income statements, balance sheets, and cash flow statements, along with key financial ratios and analysis. The company reported $71.6M in revenue, a net loss of $48.6M, and a low financial health score due to thin profitability and liquidity concerns. Despite negative operating income and cash flow, RCEL achieved a strong return on equity.
Wall Street experts predict Avita Medical (RCEL) may surge by 29.87%: Here’s how you can approach trading
Avita Medical (RCEL) shares have risen 17.9% recently, with analysts projecting a potential 29.9% surge to an average price target of $7. While analyst price targets should be approached with caution due to their historical optimism, strong agreement among analysts and upward revisions to earnings estimates for RCEL suggest potential for further growth. The company also holds a Zacks Rank #2 (Buy), indicating a favorable outlook based on earnings estimate factors.
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade
Avita Medical Inc. (RCEL) has seen an 17.9% gain in stock price over the past four weeks, closing at $5.39. Wall Street analysts predict a potential upside of 29.9%, with a mean price target of $7. This optimism is further supported by strong agreement among analysts regarding the company's earnings prospects, leading to a Zacks Rank #2 (Buy) for RCEL.
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by Analysts
Avita Medical Inc. (NASDAQ:RCEL) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $5.50. The stock recently saw an 11.1% increase, trading at $5.39, and institutions are showing notable interest, with hedge funds and institutional investors holding 27.66% of the stock. The article details recent analyst rating changes and institutional trading activity for RCEL.
Avita Medical Targets “Progressive” 2026 Growth, Guides $80M-$85M Revenue After Headwind Year
Avita Medical (NASDAQ: RCEL) aims for "progressive" quarter-over-quarter growth in 2026, forecasting $80M-$85M revenue, an increase of 12%-19% from 2025's $71.6M, with a long-term goal of over 20% CAGR. The company plans to improve profitability and cash efficiency by cutting operating costs, targeting 83%-85% gross margins, and reducing quarterly cash burn. These efforts follow a challenging 2025 due to reimbursement issues and sales force changes, with a new $60M credit line replacing an older facility with "unachievable" covenants.
Avita Medical (NASDAQ:RCEL) CFO David O'toole Purchases 3,000 Shares of Stock
Avita Medical (NASDAQ:RCEL) CFO David O'toole recently purchased 3,000 shares of the company's stock for $12,450, increasing his total holdings to 140,127 shares. The transaction, disclosed in an SEC filing, reflects a 2.19% increase in his position. The stock traded up by 1.3% to $4.85 following the news, with the company currently holding a "Hold" consensus rating from analysts.
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
AVITA Medical, a leading therapeutic acute wound care company, announced its participation in the upcoming TD Cowen 46th Annual Health Care Conference. Interim CEO Cary Vance and CFO David O’Toole are scheduled to present and hold a fireside chat on March 4th. A webcast of the event will be available on AVITA Medical's investor relations website.
Hear AVITA Medical interim CEO, CFO at TD Cowen event
AVITA Medical (NASDAQ: RCEL) announced that interim CEO Cary Vance and CFO David O’Toole will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The presentation will include a fireside chat and will be webcast live and archived on the company's investor website. Following this news, RCEL's stock experienced a moderate negative market reaction, declining 2.47%.
CFO buys 3,000 AVITA Medical (RCEL) shares in open trade
AVITA Medical's CFO, David D. O'Toole, purchased 3,000 shares of the company's common stock at $4.15 per share on February 19, 2026. This open-market transaction increased his direct ownership stake to 140,127 shares, which includes unvested restricted stock units. The Form 4 filing indicates a positive sentiment regarding this insider trading activity.
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 earnings call transcript
This is the Q4 2025 earnings call transcript for AVITA Medical, Inc. (RCEL). The article would typically contain detailed financial results, management commentary, and possibly analyst questions and answers regarding the company's performance and outlook.
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
Avita Medical Inc. (RCEL) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's stock price, as changes in earnings potential are strongly correlated with near-term stock movements. The Zacks Rank system, which analyzes earnings estimate revisions, has a strong track record of identifying stocks poised for market-beating returns.
Avita Medical (NASDAQ:RCEL) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital has reiterated a "Buy" rating for Avita Medical (NASDAQ:RCEL) with a $10 price target, suggesting a significant upside of 140.38% from its previous closing price. This rating comes amidst a mixed analyst consensus of "Hold" with an average price target of $5.50. Despite varying ratings from other firms, Avita Medical's stock jumped 11.8% on Tuesday, and the company has attracted attention from several institutional investors.
RCEL: D. Boral Capital Maintains "Buy" Rating and $10 PT | RCEL Stock News
D. Boral Capital has reaffirmed its "Buy" rating for AVITA Medical (RCEL) with a maintained price target of $10, demonstrating consistent confidence in the company's performance. This re-evaluation by analyst Jason Kolbert aligns with previous assessments and reflects a positive outlook despite some varied ratings from other analysts. AVITA Medical, primarily known for its RECELL system for burn treatment, is forecasted to have an average target price of $6.20 by Wall Street analysts, suggesting a significant upside from its current price.
Avita Medical Earnings Call Signals Stabilizing Growth
Avita Medical's Q4 earnings call presented a picture of stabilization and execution discipline rather than rapid growth for 2025, with management focusing on steady revenue expansion, cost control, and a de-risked balance sheet. The company reported full-year 2025 revenue of $71.6 million, an 11% increase, and has guided 2026 revenue to a range of $80.0–$85.0 million, assuming normalization of ReCell utilization and contributions from new products. Despite high gross margins and improved cash burn, the company remains structurally unprofitable, with Q4 revenue softness and ongoing reimbursement challenges impacting profitability.
Avita Medical (RCEL) TTM US$48.6m Loss Tests Bullish Profitability Narratives
Avita Medical (RCEL) reported a Q4 revenue of US$17.6 million and a basic EPS loss of US$0.38, culminating in a full-year net loss of US$48.6 million for FY 2025. Despite analysts forecasting significant revenue and earnings growth, the company faces challenges including widening losses, negative equity, and a short cash runway, raising concerns about its financial stability. The stock trades at a low price-to-sales ratio compared to industry averages, which bulls see as an opportunity, but financial risks temper this optimism.
AVITA Medical, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:RCEL) 2026-02-12
AVITA Medical, Inc. (RCEL) released its Q4 2025 earnings call presentation on February 12, 2026. The company reported an EPS of -$0.38, which beat estimates by $0.00, and revenue of $17.60M, beating estimates by $150.90K despite a 4.65% year-over-year decrease. The slide deck was published in conjunction with their earnings call.
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (ASX: AVH, NASDAQ: RCEL) announced an investor webinar briefing set for February 18, 2026, at 2:00 p.m. Pacific Standard Time, covering financial and business results from its recent fourth-quarter and full-year 2025 earnings. Interim CEO Cary Vance and CFO David O'Toole will lead the presentation, which will include a Q&A session. A replay will be available on the company's website.
Avita's Road to Profitability Is in Sight
Avita Medical is expected to achieve profitability, driven by the strong performance and competitive advantages of its RECELL product. RECELL, a "spray-on skin" treatment, offers clinical effectiveness, ease of use, and a favorable price point compared to traditional skin grafts, posing a challenge to the current standard of care for larger burns. The company has also secured a new debt facility to further de-risk its path to positive cash flow.
Ask AVITA Medical’s interim CEO your questions in Feb. 18 investor webinar Q&A
AVITA Medical (NASDAQ: RCEL) will host an investor webinar on February 18, 2026, featuring Interim CEO Cary Vance and CFO David O'Toole. They will discuss the company's fourth-quarter and full-year 2025 financial and business results, followed by a Q&A session where participants can submit questions beforehand. The announcement led to a positive market reaction, with RCEL's stock gaining 11.29%.
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 Earnings Call Transcript
AVITA Medical (NASDAQ:RCEL) reported Q4 and full-year 2025 earnings, with Q4 revenue of $17.6 million and full-year revenue of $71.6 million, exceeding expectations for EPS. The company emphasized a new focus on disciplined execution and commercial refinement, overcoming reimbursement uncertainties that affected 2025. They provided 2026 revenue guidance of $80-85 million, driven by increased utilization of their ReCell, CoHiliX, and PermeDerm products within existing accounts.
Avita Medical (NASDAQ:RCEL) Issues Earnings Results, Misses Expectations By $0.02 EPS
Avita Medical (NASDAQ:RCEL) announced its quarterly earnings, reporting a ($0.38) EPS, missing analyst expectations by $0.02. Following the news, the stock declined by approximately 3.4% to $3.71. Analyst sentiment remains mixed, with an average "Hold" rating and institutional investors holding about 27.66% of the stock.
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
AVITA Medical (NASDAQ: RCEL, ASX: AVH) reported its Q4 and full-year 2025 financial results, showing total revenue of $17.6 million for Q4 and $71.6 million for the full year, an 11% increase from 2024. The company reduced operating expenses and improved cash efficiency, with a net loss of $48.6 million for the year. AVITA Medical also refinanced its debt under a new credit facility with Perceptive Advisors LLC, securing up to $60 million to support long-term growth and entering 2026 with a focus on execution-led growth.
AVITA Medical (RCEL) Q4 2025 Earnings Transcript
AVITA Medical (RCEL) reported Q4 2025 revenue of $17.6 million and full-year revenue of $71.6 million, an 11% annual increase, in line with guidance. The company achieved significant operational improvements, including reduced operating expenses and improved cash efficiency, positioning it for execution-driven growth in 2026. Key advancements include resolved reimbursement clarity for its ReCell product, expanded multi-product adoption, and a new credit facility that reduces covenant risk.
AVITA Medical, Inc. SEC 10-K Report
AVITA Medical, Inc. has released its annual 10-K report, detailing an 11% increase in total revenues to $71.6 million and a 21% decrease in net loss to $48.6 million. The company expanded its product portfolio with PermeaDerm and Cohealyx, received several FDA and CE mark approvals for its RECELL technology, and is focusing on increasing market penetration and achieving long-term profitability despite facing significant competitive, financial, and regulatory risks.
Avita Medical Inc. (RCEL) Stock Falls on Q4 2025 Earnings
Avita Medical Inc. (RCEL) reported its Q4 2025 earnings, showing a revenue decrease of 4.3% year-over-year and a significant operating profit decline. The company's diluted earnings per share missed consensus estimates, leading to a stock price drop of 3.05% after market close. Insider trading data indicates more purchases than sales in the last six months, while institutional investors show mixed activity with some major exits and additions.
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
AVITA Medical announced its financial results for the fourth quarter and full year ended December 31, 2025, showing fourth-quarter revenue of $17.8 million and full-year revenue of approximately $60.8 million. The company reported continued progress in cash efficiency and reduced operating expenses, along with the refinancing of its debt with a new credit facility. AVITA Medical remains focused on disciplined cash management, sharp execution, and accelerating commercial momentum in its core U.S. burn and trauma markets for 2026.
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating
Lake Street has increased its price target for AVITA Medical, Inc. (RCEL) to $3.50 from $3 while maintaining a Hold rating. This decision follows the company's recent debt refinancing, which helped alleviate short-term liquidity concerns. AVITA Medical is projecting FY26 revenue of $80 million to $85 million, up from $71.6 million in FY24, and aims for execution-led growth after strengthening its financial foundation and clinical pipeline.
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating
Lake Street has increased its price target for AVITA Medical, Inc. (RCEL) to $3.50 from $3.00, while reiterating a Hold rating. This adjustment follows the company's recent debt refinancing, which has eased short-term liquidity concerns. The firm awaits Q4 results and clarity on reimbursement trends for a more optimistic outlook.
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating
Lake Street has increased its price target on AVITA Medical, Inc. (RCEL) to $3.50 from $3 while keeping a Hold rating, attributing the change to the company's recent debt refinancing which eased liquidity concerns. The firm is awaiting Q4 results and clearer reimbursement trend commentary before taking a more positive stance. AVITA Medical projects FY26 revenue of $80 million to $85 million, emphasizing a transition to execution-led growth following efforts to stabilize revenue and improve financial flexibility.
Avita Medical (RCEL) to Release Quarterly Earnings on Thursday
Avita Medical (RCEL) is set to release its Q4 2025 earnings before market open on Thursday, February 12th, with analysts forecasting an EPS of ($0.36) and revenue of $26.27 million. The company missed estimates in the prior quarter and analysts expect a full-year EPS of -$1, improving to $0 for the next fiscal year. RCEL stock recently traded at $4.08, down 5.1%, and currently holds an average "Hold" rating from analysts with a mean price target of $5.50.
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Rating of "Hold" from Brokerages
Five analysts currently rate Avita Medical (NASDAQ:RCEL) with a "Hold" consensus, with an average 12-month price target of $5.50, despite some divergent opinions including a $10.00 buy target from D. Boral Capital. The company recently missed quarterly earnings expectations, reporting ($0.46) EPS against a ($0.43) forecast and $17.06 million in revenue compared to an expected $29.39 million. Avita Medical, a regenerative medicine company focused on cell-based therapies, had an opening stock price of $4.41 and a market capitalization of $134.46 million.
AVITA Medical Announces Changes to its Board of Directors
AVITA Medical has announced changes to its Board of Directors, welcoming Joe Woody as a new non-executive Director and marking the retirement of Lou Panaccio. Woody brings extensive experience in the medical technology sector, having served as CEO of Avanos Medical and Acelity Holdings. The company expects his commercial excellence and leadership background to be invaluable for its continued growth in acute wound care solutions.
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
AVITA Medical Inc. (ASX: AVH, NASDAQ: RCEL) presented 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the first integrated use of its RECELL, PermeaDerm, and Cohealyx technologies. The data highlights improved healing, reduced complications, and shorter hospital stays in burn and complex wound care, with new histological findings supporting PermeaDerm and Cohealyx for wound bed preparation. These presentations underscore the effectiveness and practical applications of AVITA Medical's advanced wound care solutions.
AVITA Medical (RCEL) Analyst Rating: Maintained 'Buy' with $10 PT
D. Boral Capital has reaffirmed its "Buy" rating for AVITA Medical (RCEL) and maintained a $10 price target, with analyst Jason Kolbert making no changes from his previous recommendation. This aligns with other recent analyst ratings, including a "Hold" from Lake Street with a raised price target to $3.50, and earlier adjustments by D. Boral Capital and BTIG. AVITA Medical, known for its RECELL system, is primarily focusing on the US market for its burn treatment device, despite having product approval in several other countries.
D. Boral Capital Reaffirms Buy Rating for Avita Medical (NASDAQ:RCEL)
D. Boral Capital has reissued a "Buy" rating for Avita Medical (NASDAQ:RCEL), setting a price target of $10.00, which suggests a potential upside of 125.23%. This rating contrasts with the broader analyst consensus of "Hold" and an average price target of $5.50. The company recently missed its quarterly EPS and revenue estimates, and institutional investors own 27.66% of its shares.
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
AVITA Medical announced data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the first surgeon-reported integrated use of its three technologies: RECELL, PermeaDerm, and Cohealyx. The presentations highlighted how combining these technologies benefits patients and facilities, while new clinical and tissue-level data further supported the effectiveness of PermeaDerm and Cohealyx in wound bed preparation. Additionally, analyses demonstrated RECELL's consistent trends in improving healing, reducing complications, and shortening hospital stays across various studies.
First three-part AVITA burn care path cuts painful dressing changes
AVITA Medical (NASDAQ: RCEL) presented data at the 2026 Boswick Burn & Wound Symposium, showcasing the first integrated use of their RECELL, PermeaDerm, and Cohealyx technologies in single care pathways for burn patients. The data highlights reduced hospital stays, faster healing, and fewer complications with RECELL, along with initial histological findings supporting PermeaDerm and Cohealyx for wound preparation. This integrated approach is significant for improving care, especially in challenging cases and rural settings, by reducing painful dressing changes and follow-up appointments.
